Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000, 343: 1594-1602. 10.1056/NEJM200011303432202.
Article
CAS
PubMed
Google Scholar
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999, 354: 1932-1939. 10.1016/S0140-6736(99)05246-0.
Article
CAS
PubMed
Google Scholar
St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC: The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002, 46: 1451-1459. 10.1002/art.10302.
Article
CAS
PubMed
Google Scholar
Durez P, Van den Bosch F, Corluy L, Veys EM, De Clerck L, Peretz A, Malaise M, Devogelaer JP, Vastesaeger N, Geldhof A, Westhovens R: A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology (Oxford). 2005, 44: 465-468.
Article
CAS
Google Scholar
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324.
Article
CAS
PubMed
Google Scholar
Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992, 30: 473-483.
Article
PubMed
Google Scholar
Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38: 44-48.
Article
CAS
PubMed
Google Scholar
Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, van Riel PL, Tugwell P: A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003, 42: 244-257.
Article
CAS
Google Scholar
Aletaha D, Nell VPK, Stamm R, Uffmann M, Pflugbeil S, Machold K, Smolen S: Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activitiy score. Arthritis Res Ther. 2005, 7: R796-R806. 10.1186/ar1740.
Article
PubMed Central
CAS
PubMed
Google Scholar
Wolfe F: Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol. 1997, 24: 1477-1485.
CAS
PubMed
Google Scholar
DAS-Score.NL. [http://www.das-score.nl/www.das-score.nl/index.html]
van Riel PL, van Gestel AM, van de Putte LB: Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. Br J Rheumatol. 1996, 35 (Suppl 2): 4-7.
Article
PubMed
Google Scholar
Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, et al: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993, 36: 729-740.
Article
CAS
PubMed
Google Scholar
Harper R, Reeves B: Reporting of precision of estimates for diagnostic accuracy: a review. BMJ. 1999, 318: 1322-1323.
Article
PubMed Central
CAS
PubMed
Google Scholar
Hanley JA, McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983, 148: 839-843.
Article
CAS
PubMed
Google Scholar
Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993, 39: 561-577.
CAS
PubMed
Google Scholar
Pepe MS, Longton G, Anderson GL, Schummer M: Selecting differentially expressed genes from microarray experiments. Biometrics. 2003, 59: 133-142. 10.1111/1541-0420.00016.
Article
PubMed
Google Scholar
Hosmer DW, Lemeshow S: Chapter 4. Applied Logistic Regression. 2000, New York: John Wiley & Sons, 2
Chapter
Google Scholar
van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LB: Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990, 49: 916-920.
Article
PubMed Central
CAS
PubMed
Google Scholar
van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB: Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 1993, 20: 579-581.
CAS
PubMed
Google Scholar
Salaffi F, Peroni M, Ferraccioli GF: Discriminating ability of composite indices for measuring disease activity in rheumatoid arthritis: a comparison of the Chronic Arthritis Systemic Index, Disease Activity Score and Thompson's articular index. Rheumatology (Oxford). 2000, 39: 90-96.
Article
CAS
Google Scholar
Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004, 364: 263-239. 10.1016/S0140-6736(04)16676-2.
Article
PubMed
Google Scholar
Fuchs HA: The use of the disease activity score in the analysis of clinical trials in rheumatoid arthritis. J Rheumatol. 1993, 20: 1863-1866.
CAS
PubMed
Google Scholar
Fransen J, van Riel PL: Are better endpoints and better design of clinical trials needed?. Best Pract Res Clin Rheumatol. 2004, 18: 97-109. 10.1016/j.berh.2003.09.011.
Article
PubMed
Google Scholar
Gossec L, Dougados M, Goupille P, Cantagrel A, Sibilia J, Meyer O, Sany J, Daures JP, Combe B: Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis. 2004, 63: 675-680. 10.1136/ard.2003.010611.
Article
PubMed Central
CAS
PubMed
Google Scholar
Welsing PM, Landewe RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, Swinkels HL, van der Heijde DM: The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum. 2004, 50: 2082-2093. 10.1002/art.20350.
Article
PubMed
Google Scholar
Fransen J, Stucki G, van Riel P: The merits of monitoring: should we follow all our rheumatoid arthritis patients in daily practice?. Rheumatology (Oxford). 2002, 41: 601-604.
Article
CAS
Google Scholar
Wolfe F, Cush JJ, O'Dell JR, Kavanaugh A, Kremer JM, Lane NE, Moreland LW, Paulus HE, Pincus T, Russell AS, Wilskie KR: Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol. 2001, 28: 1423-1430.
CAS
PubMed
Google Scholar
van Riel PL, Schumacher HR: How does one assess early rheumatoid arthritis in daily clinical practice?. Best Pract Res Clin Rheumatol. 2001, 15: 67-76. 10.1053/berh.2000.0126.
Article
CAS
PubMed
Google Scholar
Smolen JS, Aletaha D: Patients with rheumatoid arthritis in clinical care. Ann Rheum Dis. 2004, 63: 221-225. 10.1136/ard.2003.012575.
Article
PubMed Central
CAS
PubMed
Google Scholar
Den Broeder AA, Creemers MC, van Gestel AM, van Riel PL: Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. Rheumatology (Oxford). 2002, 41: 638-642.
Article
CAS
Google Scholar